IP Library Granted Patent US 11,136,555
Granted Patent B2
US 11,136,555 · App. 15/905,982 · Granted Oct 5, 2021

Compositions and methods for differentiation of human pluripotent stem cells into desired cell types

Inventor: Minoru S. H. Ko (Baltimore, MD)
Assignee: ELIXIRGEN SCIENTIFIC, INC.
C12N5/0696C07K14/00C12N5/067C12N5/0619C12N5/0647C12N5/0658C12N15/113C12N15/85C12N15/86C12N2015/8518C12N2310/14C12N2501/60C12N2501/602C12N2501/603C12N2506/08C12N2506/1323C12N2506/14C12N2506/45C12N2510/00C12N2523/00C12N2760/18741C12N2760/18843C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,136,555
App. No.
15/905,982
Granted
Oct 5, 2021
Kind
B2
Abstract

In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being stable and highly efficient. The use of complicated culture steps is a large problem. In addition, there are also large problems in, for example, that the speed of cell differentiation is low, and hence long-period culture is required, and that the differentiation efficiency is low, and hence it is difficult to obtain a sufficient number of required cells. A method of inducing differentiation into a desired cell type, which induces differentiation within a short period of time and with high efficiency by the use of a Sendai virus vector capable of expressing a transcription factor, and as required, the use of a pluripotent stem cell in which an expression amount of a POU5F1 protein has been substantially removed or reduced, is provided.

Claims (11)

1. A method of differentiating a pluripotent stem cell into a skeletal muscle cell, comprising:

a) adding a Sendai virus vector encoding a transcription factor MYOD1 to a pluripotent stem cell in a cell culture medium;

b) culturing the pluripotent stem cell to differentiate the pluripotent stem cell into the skeletal muscle cell; and

c) adding a nucleic acid encoding a compound having an action of substantially removing or reducing an expression amount of POU5F1 protein to the pluripotent stem cell,

wherein differentiation efficiency of the skeletal muscle cell is 75% or more.

2. The method according to claim 1 , wherein the nucleic acid encoding the compound having an action of substantially removing or reducing an expression amount of a POU5F1 protein encodes siRNA against POU5F1.

3. The method according to claim 1 , wherein the Sendai virus vector is temperature-sensitive.

4. The method according to claim 1 , wherein the adding the Sendai virus vector encoding the transcription factor MYOD1 to the pluripotent stem cell in the cell culture medium is performed once.

5. The method according to claim 1 ,

wherein differentiation efficiency of the skeletal muscle cell is 75% or more, and

wherein one kind of cell culture medium is used.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2019
From: ELIXIRGEN, LLC
To: ELIXIRGEN SCIENTIFIC, INC.
Reel/Frame 050058/0816 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2018
From: KO, MINORU S.H.
To: ELIXIRGEN, LLC
Reel/Frame 045181/0449 →
Continuity (3)
Provisional Application 62523324 · Jun 22, 2017
Provisional Application 62465188 · Mar 1, 2017
Related Publication 20180251735A1 · Sep 6, 2018